| Grant number: | 12/06421-5 |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| Start date: | July 01, 2012 |
| End date: | December 31, 2012 |
| Field of knowledge: | Health Sciences - Medicine - Medical Clinics |
| Principal Investigator: | Silvia Regina Caminada de Toledo |
| Grantee: | Alini Trujillo Paolillo |
| Host Institution: | Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil |
Abstract Osteosarcoma (OS) is the most frequent bone tumor in children and adolescents. Despite recent advances in cancer treatment, its progress has reached a plateau. Drug resistance and unfavorable clinical results affect nearly 50% of all patients. Studies looking for changes that may be used as prognostic factors and therapeutic targets, can improve the cure in high-risk patients and minimize the toxicity in low-risk patients. There are two families of genes, GST and CYP, that are known to participate in the drug metabolism of approximately 95% of all drugs. Thus, our study aims to relate the polymorphisms of GSTM1, GSTT1, GSTM3, CYP1A2, CYP3A5, and CYP2C9 genes with the therapeutic response, clinical outcome, toxicity development, and survival, and to validate this in a controlled sample of 50 patients, which were submitted to the same treatment protocol and have all the clinical data available. The genes identified as important may, in the future, be used in the improvement of the treatment of patients with OS.(AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |